Position
Director
Company
Enliven Therapeutics
BurlingameBiotechnologyHealthcareHealth CareScience And EngineeringTherapeuticsDescription
On October 14, 2026, Enliven Therapeutics announced the appointment of Kristine Ball to its Board of Directors. Ms. Ball will serve as a Class II director, with her term set to expire at the 2028 annual meeting of stockholders
Quick answer
Enliven Therapeutics Appoints Kristine Ball as Class II Director (October 14, 2026). Enliven Therapeutics is based in Burlingame, California, United States.
- Who is the new Director at Enliven Therapeutics?
- Enliven Therapeutics named Kristine Ball Director, announced October 14, 2026.
- What did Enliven Therapeutics announce on October 14, 2026?
- On October 14, 2026, Enliven Therapeutics announced the appointment of Kristine Ball to its Board of Directors.
- What does Enliven Therapeutics do?
- Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better.
- Where is Enliven Therapeutics based?
- Enliven Therapeutics is based in Burlingame, California, United States.
- Which similar companies made leadership changes around the same time?
- Verastem Oncology (October 14, 2026), Tempest Therapeutics (October 19, 2026), CytoDyn (October 19, 2026) and Crispr Therapeutics (October 19, 2026) also announced leadership changes within 45 days of Enliven Therapeutics.
Source: Fundz verified event record.
Other recent leadership changes in Healthcare and Science And Engineering
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Verastem Oncology Appoints Michael P. Bailey as Chief Executive Officer (October 14, 2026)
- Tempest Therapeutics Appoints John Frederick as Class III Director (October 19, 2026)
- CytoDyn Inc. Appoints Robert E. Hoffman as CEO (October 19, 2026)
- CRISPR Therapeutics Appoints Andrew J. Silver as Chief Financial Officer (October 19, 2026)
- Gyre Therapeutics Appoints Ying Luo as CEO and Thomas Eastling as CFO (October 22, 2026)
- Retension Pharmaceuticals Appoints Robert Wong as Chief Accounting Officer (October 23, 2026)
Who to call at Enliven Therapeutics, and when
A new leader at Enliven Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day Enliven Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Enliven Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Enliven Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Enliven Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Enliven Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.